Providence Therapeutics announces exec appointment

1 February 2023

Canadian mRNA-focussed biotech firm Providence Therapeutics today announced the appointment of Robert Georgantas III as president and chief technology officer (CTO).

“Robert’s experience in drug discovery, clinical development, and management at the executive level across several biotech and large pharmaceutical companies will be invaluable as we continue advancing our pipeline of mRNA vaccines,” said Brad Sorenson, chief executive of Providence Therapeutics. “With the expansion of our pipeline of mRNA vaccines for cancer and infectious diseases and our COVID-19 vaccine candidate moving forward into Phase III trials this year, Robert’s insights will be crucial from a strategic and technical advancement perspective,” he added.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK